✦ LIBER ✦

Phase I/II trial of combined 131I anti-CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma

✍ Scribed by Bharat B. Mittal; Michael A. Zimmer; Vythialingam Sathiaseelan; Al B. Benson III; Raj R. Mittal; Swati Dutta; Steven T. Rosen; Stewart M. Spies; Joanne M. Mettler; Mark W. Groch

Publisher: John Wiley and Sons
Year: 1996
Tongue: English
Weight: 939 KB
Volume: 78
Category: Article
ISSN: 0008-543X
DOI: 10.1002/(sici)1097-0142(19961101)78:9<1861::aid-cncr4>3.0.co;2-i

No coin nor oath required. For personal study only.

✦ Synopsis

BACKGROUND. This pilot project was undertaken to evaluate the toxicity of and tumor response to combined 13'1 anti-carcinoembryonic antigen monoclonal antibody ('"I anti-CEA RMoAb) and hyperthermia in patients with metastatic colorectal adenocarcinoma.

📜 SIMILAR VOLUMES

Phase-I/II radio-immunotherapy study wit

Phase-I/II radio-immunotherapy study with iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab′)2 in patients with non-resectable liver metastases from colorectal cancer

✍ Marc Ychou; André Pelegrin; Patrick Faurous; Bruno Robert; Jean-Claude Saccavini 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 85 KB 👁 2 views

Experimental studies in nude mice with human coloncarcinoma grafts demonstrated the therapeutic efficiency of F(abЈ) 2 fragments to carcinoembryonic antigen (CEA) labeled with a high dose of 131 Iodine. A phase I/II study was designed to determine the maximum tolerated dose of 131 I-labeled F(abЈ) 2

Phase I/II trial of 131I-MN-14 F(ab)2 an

Phase I/II trial of 131I-MN-14 F(ab)2 anti–carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma

✍ Malik E. Juweid; George Hajjar; Lawrence C. Swayne; Robert M. Sharkey; Samer Sul 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 464 KB 👁 1 views

## BACKGROUND. Monoclonal antibodies (MAbs) against carcinoembryonic antigen (CEA) have been recognized as targeting agents for medullary thyroid carcinoma (MTC). This Phase I/II study was initiated to determine the safety, maximum tolerated dose (MTD), and therapeutic potential of 131 I-MN-14 F(ab

Phase I/II trial of dexverapamil, epirub

Phase I/II trial of dexverapamil, epirubicin, and granulocyte-macrophage–colony stimulating factor in patients with advanced pancreatic adenocarcinoma

✍ Gabriela Kornek; Markus Raderer; Thomas Schenk; Johann Pidlich; Franz Schulz; Se 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 659 KB

Oxaliplatin plus raltitrexed in patients

Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma : Results of a Phase I–II trial

✍ Werner Scheithauer; Gabriela V. Kornek; Herbert Ulrich-Pur; Melitta Penz; Markus 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 2 views

Platinum-free combination chemotherapy i

Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma : A Phase I/II trial of gemcitabine, paclitaxel, and methotrexate

✍ Primo N. Lara Jr; Frederick J. Meyers; Lisa Y. Law; Nancy A. Dawson; Joan Housto 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 2 views

## Abstract ## BACKGROUND Platinum‐based regimens have improved response rates and survival in patients with advanced transitional cell carcinoma (TCC) of the urothelial tract. However, the toxicities of platinum‐based chemotherapy are considerable. Regimens with reduced toxicity that are applicab